Notably, a recent pharmacoepidemiology study suggested that cholinesterase inhibitors, specific Alzheimer's dementia therapies that block the action of cholinesterases and activate the cholinergic anti-inflammatory pathway, were associated with a lower risk of CKD progression in patients with Alzheimer's disease [104]. This evidence concerns the gene BCHE and Alzheimer disease.